Skip to main content
Journal cover image

Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency.

Publication ,  Journal Article
Mummy, DG; Carey, KJ; Evans, MD; Denlinger, LC; Schiebler, ML; Sorkness, RL; Jarjour, NN; Fain, SB
Published in: J Allergy Clin Immunol
October 2020

BACKGROUND: There is an unmet need for an objective biomarker to predict asthma exacerbations. OBJECTIVE: Our aim was to assess the ventilation defect percent (VDP) on hyperpolarized helium-3 magnetic resonance imaging as a predictor of exacerbation frequency following imaging. METHODS: Subjects underwent hyperpolarized helium-3 and conventional clinical measurements, including pulmonary function tests, during a period of disease stability, and exacerbations were recorded prospectively over the following 2 years. We used a Poisson regression tree model to estimate an optimal VDP threshold for classifying subjects into high- versus low-exacerbation groups and then used statistical regression to compare this VDP threshold against conventional clinical measures as predictors of exacerbations. RESULTS: A total of 67 individuals with asthma (27 males and 40 females, 28 with mild-to-moderate asthma and 39 with severe asthma) had a median VDP of 3.75% (1.2% [first quartile]-7.9% [third quartile]). An optimal VDP threshold of 4.28% was selected on the basis of the maximum likelihood estimation of the regression tree model. Subjects with a VDP greater than 4.28% (n = 32) had a median of 1.5 exacerbations versus 0.0 for subjects with a VDP less than 4.28% (n = 35). In a stepwise multivariate regression model, a VDP greater than 4.28% was associated with an exacerbation incidence rate ratio of 2.5 (95% CI = 1.3-4.7) versus a VDP less than or equal to 4.28%. However, once individual medical history was included in the model, VDP was no longer significant. Nonetheless, VDP may provide an objective and complementary quantitative marker of individual exacerbation risk that is useful for monitoring individual change in disease status, selecting patients for therapy, and assessing treatment response. CONCLUSION: VDP measured with magnetic resonance imaging shows promise as a biomarker of prospective asthma exacerbations.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

October 2020

Volume

146

Issue

4

Start / End Page

831 / 839.e6

Location

United States

Related Subject Headings

  • Young Adult
  • Severity of Illness Index
  • Respiratory Function Tests
  • Prognosis
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Lung
  • Isotopes
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Mummy, D. G., Carey, K. J., Evans, M. D., Denlinger, L. C., Schiebler, M. L., Sorkness, R. L., … Fain, S. B. (2020). Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency. J Allergy Clin Immunol, 146(4), 831-839.e6. https://doi.org/10.1016/j.jaci.2020.02.029
Mummy, David G., Katherine J. Carey, Michael D. Evans, Loren C. Denlinger, Mark L. Schiebler, Ronald L. Sorkness, Nizar N. Jarjour, and Sean B. Fain. “Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency.J Allergy Clin Immunol 146, no. 4 (October 2020): 831-839.e6. https://doi.org/10.1016/j.jaci.2020.02.029.
Mummy DG, Carey KJ, Evans MD, Denlinger LC, Schiebler ML, Sorkness RL, et al. Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency. J Allergy Clin Immunol. 2020 Oct;146(4):831-839.e6.
Mummy, David G., et al. “Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency.J Allergy Clin Immunol, vol. 146, no. 4, Oct. 2020, pp. 831-839.e6. Pubmed, doi:10.1016/j.jaci.2020.02.029.
Mummy DG, Carey KJ, Evans MD, Denlinger LC, Schiebler ML, Sorkness RL, Jarjour NN, Fain SB. Ventilation defects on hyperpolarized helium-3 MRI in asthma are predictive of 2-year exacerbation frequency. J Allergy Clin Immunol. 2020 Oct;146(4):831-839.e6.
Journal cover image

Published In

J Allergy Clin Immunol

DOI

EISSN

1097-6825

Publication Date

October 2020

Volume

146

Issue

4

Start / End Page

831 / 839.e6

Location

United States

Related Subject Headings

  • Young Adult
  • Severity of Illness Index
  • Respiratory Function Tests
  • Prognosis
  • Middle Aged
  • Male
  • Magnetic Resonance Imaging
  • Lung
  • Isotopes
  • Humans